FDA rejects application for new oral MR imaging contrast agent
Biotechnology firm Ascelia Pharma is working to roll out Orviglance, a novel manganese-based product for visualizing focal liver lesions during MRI, but faced a recent setback.
Biotechnology firm Ascelia Pharma is working to roll out Orviglance, a novel manganese-based product for visualizing focal liver lesions during MRI, but faced a recent setback.
What's Your Reaction?
